HLB Therapeutics Co.,Ltd. (115450.KQ)
KRW 10680.0
(-2.11%)
KRW 10680.0
(-2.11%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 53.74 Billion KRW | 26.76% |
| 2022 | 42.4 Billion KRW | -2.72% |
| 2021 | 43.58 Billion KRW | 1.53% |
| 2020 | 42.92 Billion KRW | -27.2% |
| 2019 | 58.96 Billion KRW | 35.29% |
| 2018 | 43.58 Billion KRW | 154.1% |
| 2017 | 17.15 Billion KRW | -3.15% |
| 2016 | 17.71 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 11.66 Billion KRW | -8.57% |
| 2024 Q1 | 12.75 Billion KRW | -18.61% |
| 2023 FY | 53.74 Billion KRW | 26.76% |
| 2023 Q2 | 8.61 Billion KRW | -33.68% |
| 2023 Q3 | 19.19 Billion KRW | 122.95% |
| 2023 Q4 | 15.67 Billion KRW | -18.37% |
| 2023 Q1 | 12.98 Billion KRW | -0.13% |
| 2022 Q2 | 11.9 Billion KRW | 10.77% |
| 2022 FY | 42.4 Billion KRW | -2.72% |
| 2022 Q4 | 12.99 Billion KRW | -46.7% |
| 2022 Q3 | 24.38 Billion KRW | 104.93% |
| 2022 Q1 | 10.74 Billion KRW | -12.41% |
| 2021 Q4 | 12.26 Billion KRW | -33.94% |
| 2021 Q3 | 18.56 Billion KRW | 0.0% |
| 2021 FY | 43.58 Billion KRW | 1.53% |
| 2020 FY | 42.92 Billion KRW | -27.2% |
| 2019 FY | 58.96 Billion KRW | 35.29% |
| 2018 FY | 43.58 Billion KRW | 154.1% |
| 2017 FY | 17.15 Billion KRW | -3.15% |
| 2016 FY | 17.71 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| HLB Co., Ltd. | 42.9 Billion KRW | -25.288% |
| iNtRON Biotechnology, Inc. | 9.58 Billion KRW | -460.736% |
| BINEX Co., Ltd. | 154.82 Billion KRW | 65.284% |
| Bioneer Corporation | 263.23 Billion KRW | 79.581% |
| Anterogen.Co.,Ltd. | 6.5 Billion KRW | -726.877% |
| MEDIPOST Co., Ltd. | 68.64 Billion KRW | 21.698% |
| CrystalGenomics, Inc. | 4.87 Billion KRW | -1001.717% |
| Helixmith Co., Ltd | 4.2 Billion KRW | -1179.245% |
| Chabiotech Co.,Ltd. | 953.95 Billion KRW | 94.366% |
| Medy-Tox Inc. | 221.12 Billion KRW | 75.692% |
| Peptron, Inc. | 3.34 Billion KRW | -1508.342% |
| Amicogen, Inc. | 159.9 Billion KRW | 66.387% |
| Genexine, Inc. | 4.42 Billion KRW | -1114.222% |
| LegoChem Biosciences, Inc. | 34.14 Billion KRW | -57.411% |
| ALTEOGEN Inc. | 96.52 Billion KRW | 44.315% |
| PharmaResearch Co., Ltd. | 261.01 Billion KRW | 79.407% |
| SillaJen, Inc. | 3.93 Billion KRW | -1264.342% |
| JETEMA, Co., Ltd. | 58.71 Billion KRW | 8.459% |
| OliX Pharmaceuticals,Inc | 17.06 Billion KRW | -214.98% |
| Genomictree Inc. | 3.41 Billion KRW | -1472.525% |
| MedPacto, Inc. | - KRW | -Infinity% |
| D&D Pharmatech | 18.67 Billion KRW | -187.781% |
| EASY BIO,Inc. | 165.38 Billion KRW | 67.501% |
| GI Innovation, Inc. | 5.31 Billion KRW | -910.539% |